Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NECTAR2: Low Dose Tafenoquine for Malaria Transmission
NCT04609098Phase 2Completed
- Sponsor
- London School of Hygiene & Tropical Medicine
- Start
- Oct 2020
- Primary completion
- Dec 2020
- Modality
- Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of tafenoquine in Malaria (4 arms), sponsored by London School of Hygiene & Tropical Medicine. Primary endpoint: Change in mosquito infectivity assessed through membrane feeding assays at Day 7. Started Oct 2020; status: completed.
02
Drugs
tafenoquine
03
Conditions
Malaria
Beyond the preview
Go deeper on NCT04609098.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04609098.